

## Capital Raise Update

**Sydney, Australia – 21 November 2023:** Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) refers to its capital raising announcement dated 15 November 2023 (**Placement**). The Company notes that, in the announcement, it advised that settlement of Tranche One of the Placement had been delayed as a result of an administrative delay in the transfer of funds from outside Australia. The announcement advised that the Company expected Tranche One to settle on or around 20 November 2023.

The Company advises that Tranche One of the Placement did not settle on 20 November 2023. The delay in settlement has arisen as a result of a delay in receipt of funds from the Placement’s cornerstone investor, Antah Healthcare Group (**Antah**).

Bod has been advised by Antah that the delay has arisen as a result of a delay in receiving a Monetary Authority of Singapore (**MAS**) approval that is required by Antah to transfer the funds. Antah has confirmed to Bod that it has been advised that the MAS approval is a formality and will occur imminently. Antah has also confirmed to Bod that its bank has its irrevocable authority to transfer Antah’s Tranche One Placement commitment of ~\$0.44m to Bod immediately on receipt of the MAS approval.

Antah has re-confirmed its commitment to the Placement in letters from its Group Managing Director to Bod in letters dated 14 November 2023 and 17 November 2023.

Bod is working with Antah to finalise the fund transfer and settlement of Tranche One of the Placement in the coming days and will advise the market as soon as settlement has occurred.

**This announcement has been approved by the Chairman of Bod Science Limited.**

**-ENDS-**

### About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
Info@bodaustralia.com  
+61 2 9199 5018